生物制药公司Hoth Therapeutics, Inc. (NASDAQ: HOTH )今日宣布，根据与H.C. Wainwright & Co.签订的现有场内发行协议，将其普通股的最高发行总额增加500万美元。自2024年11月8日以来，该公司已根据该协议售出约270万美元的股票。

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio ...

Hoth Therapeutics , Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that it has increased the maximum aggregate offering price of its common stock by $5 million under its existing At ...

NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the ...

Hoth Therapeutics Inc., a micro-cap biotech company, saw its stock price surge over 200% on Tuesday to become the top gainer across U.S. exchanges. Trading volume skyrocketed to 665 times its ...

Hoth Therapeutics (HOTH) announced its collaboration with OnTargetx R&D to advance research for its cancer-fighting therapeutic, HT-KIT.

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...